Cullinan Therapeutics annual r&d spending
2020
2021
2022
2023
2024
2025
Cullinan Therapeutics R&D Spending Growth & History (CGEM)
Cullinan Therapeutics's r&d spending was $187.4M for fiscal 2025.
View full Cullinan Therapeutics company overviewCullinan Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $187.4M | $44.5M | +31.14% |
| 2024 | 2024-12-31 | $142.9M | −$5.3M | −3.55% |
| 2023 | 2023-12-31 | $148.2M | $56.2M | +61.13% |
| 2022 | 2022-12-31 | $91.9M | $34.2M | +59.21% |
| 2021 | 2021-12-31 | $57.8M | $14.5M | +33.65% |
| 2020 | 2020-12-31 | $43.2M | — | — |
Cullinan Therapeutics quarterly r&d spending
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $44.4M | −$16.6M | −27.19% |
| Q1 2026 | 2026-03-31 | $42.1M | $664,000 | +1.60% |
| Q4 2025 | 2025-12-31 | $42.9M | $2.5M | +6.06% |
| Q3 2025 | 2025-09-30 | $42.0M | $6.5M | +18.20% |
| Q2 2025 | 2025-06-30 | $61.0M | $24.8M | +68.32% |
| Q1 2025 | 2025-03-31 | $41.5M | $10.8M | +35.28% |
| Q4 2024 | 2024-12-31 | $40.5M | $5.6M | +16.20% |
| Q3 2024 | 2024-09-30 | $35.5M | $1.7M | +4.98% |
| Q2 2024 | 2024-06-30 | $36.3M | $8.9M | +32.38% |
| Q1 2024 | 2024-03-31 | $30.6M | −$21.4M | −41.17% |
| Q4 2023 | 2023-12-31 | $34.8M | $13.5M | +63.44% |
| Q3 2023 | 2023-09-30 | $33.8M | $14.1M | +71.85% |
| Q2 2023 | 2023-06-30 | $27.4M | $980,000 | +3.71% |
| Q1 2023 | 2023-03-31 | $52.1M | $27.6M | +112.32% |
| Q4 2022 | 2022-12-31 | $21.3M | $443,000 | +2.12% |
| Q3 2022 | 2022-09-30 | $19.7M | $7.0M | +55.21% |
| Q2 2022 | 2022-06-30 | $26.4M | $14.6M | +124.24% |
| Q1 2022 | 2022-03-31 | $24.5M | $12.1M | +97.63% |
| Q4 2021 | 2021-12-31 | $20.9M | $4.2M | +25.55% |
| Q3 2021 | 2021-09-30 | $12.7M | $2.8M | +27.91% |
| Q2 2021 | 2021-06-30 | $11.8M | −$718,000 | −5.75% |
| Q1 2021 | 2021-03-31 | $12.4M | $8.2M | +197.51% |
| Q4 2020 | 2020-12-31 | $16.6M | — | — |
| Q3 2020 | 2020-09-30 | $9.9M | — | — |
| Q2 2020 | 2020-06-30 | $12.5M | — | — |
| Q1 2020 | 2020-03-31 | $4.2M | — | — |
Cullinan Therapeutics r&d spending trends
Over the last five fiscal years, Cullinan Therapeutics's r&d spending increased from $43.2M to $187.4M, a change of $144.2M. The latest reported quarter, Q2 2026, shows $44.4M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cullinan Therapeutics source filings ↗